Koers Viracta Therapeutics, Inc. Nasdaq
Aandelen
US92765F1084
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 2,33 mln. 2,15 mln. | Marktkapitalisatie | 31,81 mln. 29,29 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -62 mln. -57,08 mln. | Nettowinst (verlies) 2025 * | -83 mln. -76,42 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 13,6 x |
K/w-verhouding 2024 * |
-0,7
x | K/w-verhouding 2025 * |
-0,75
x | Werknemers | 40 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,2% |
Recentste transcriptie over Viracta Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 61 | 19-09-22 |
Chief Tech/Sci/R&D Officer | - | - | |
Darrel Cohen
CTO | Chief Tech/Sci/R&D Officer | 59 | 07-08-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 01-10-07 |
Thomas Darcy
BRD | Director/Board Member | 74 | 01-02-21 |
Barry Simon
BRD | Director/Board Member | 59 | 03-03-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,37% | 49,46 mld. | |
+1,55% | 42,58 mld. | |
+49,11% | 42,49 mld. | |
-4,22% | 29,09 mld. | |
+11,57% | 26,61 mld. | |
-21,00% | 18,64 mld. | |
+7,36% | 13,16 mld. | |
+28,30% | 12,55 mld. | |
+23,80% | 12,1 mld. |